Amgen’s Humira biosim is one step closer to FDA approval. But how close is it to market?

Carly Helfand

On Monday, Amgen said the FDA had accepted its application for its biosimilar of AbbVie's , so-called ABP 501–but earlier this month, the U.S. Patent and Trademark Office shut down its challenge to 's patents.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS